Enanta Pharmaceuticals Inc. (NASDAQ:ENTA)’s share price rose 4.6% during trading on Friday . The stock traded as high as $21.98 and last traded at $21.97, with a volume of 219,832 shares trading hands. The stock had previously closed at $21.00.

ENTA has been the subject of several research reports. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th. Vetr downgraded Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $35.45 target price for the company. in a research report on Monday, April 25th. Finally, JMP Securities downgraded Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 28th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. Enanta Pharmaceuticals has an average rating of “Hold” and an average price target of $28.58.

The stock has a 50-day moving average price of $22.58 and a 200 day moving average price of $26.18. The company has a market capitalization of $426.34 million and a P/E ratio of 13.22.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, May 9th. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.10 by $0.19. During the same period last year, the firm posted $1.49 EPS. The company earned $13 million during the quarter, compared to analyst estimates of $16.80 million. The firm’s quarterly revenue was down 77.4% compared to the same quarter last year. Analysts predict that Enanta Pharmaceuticals Inc. will post $0.98 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Schroder Investment Management Group boosted its position in Enanta Pharmaceuticals by 91.8% in the fourth quarter. Schroder Investment Management Group now owns 439,303 shares of the company’s stock worth $14,506,000 after buying an additional 210,303 shares during the last quarter. Matarin Capital Management LLC purchased a new position in Enanta Pharmaceuticals during the fourth quarter worth about $4,644,000. New York State Common Retirement Fund boosted its position in Enanta Pharmaceuticals by 8.0% in the fourth quarter. New York State Common Retirement Fund now owns 133,569 shares of the company’s stock worth $4,410,000 after buying an additional 9,871 shares during the last quarter. EQIS Capital Management boosted its position in Enanta Pharmaceuticals by 382.0% in the fourth quarter. EQIS Capital Management now owns 44,836 shares of the company’s stock worth $1,480,000 after buying an additional 35,534 shares during the last quarter. Finally, First Trust Advisors LP purchased a new position in Enanta Pharmaceuticals during the fourth quarter worth about $1,374,000.

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.